RAAPID vs Reveleer (2026)
If your failure mode is choosing a risk adjustment vendor on the strength of its AI story, notice that for these two the durable asset sits in different places. RAAPID leads with architecture: neuro symbolic AI pairing machine learning with an explicit clinical knowledge graph, so every suggested HCC code links to specific MEAT based evidence in what it calls a Glass Box audit trail, an AI native product built in 2022. Reveleer leads with reach: a medical record retrieval business operating since 2009, rebuilt around NLP, whose real moat is the infrastructure that gets charts out of thousands of provider offices at volume, which a competitor cannot easily replicate. RAAPID is the AI native newcomer; Reveleer is the incumbent whose network is the asset. Both make RADV audit defense a first class use case, so the question is whether you are buying explainable coding or the retrieval engine that feeds it.
- Explainability is the architecture, not a feature: every suggested hierarchical condition category code traces to specific MEAT based clinical evidence, the exact documentation standard CMS auditors apply, which structurally blocks a code that cannot be sourced to the chart.
- It publishes both accuracy numbers, 92 percent before human review and above 98 percent after coder validation, which tells a buyer how much work the human is actually doing rather than hiding behind the post review figure.
- The design is oriented to the audit from the start, covering prospective, retrospective, and RADV audit workflows as first class rather than treating compliance as an afterthought.
- The moat is the retrieval network: operating since 2009, it gets charts out of thousands of provider organizations at volume, the piece third party analysis flags as the real integration lift and the asset a customer cannot easily replace.
- Breadth across the payer quality and risk surface, spanning HEDIS quality abstraction, risk adjustment, and RADV Independent Validation Audit submissions, where RAAPID centers on the coding and explainability layer.
- Longevity and scale as the evidence: a track record across Medicare Advantage, ACA Marketplace, and Medicaid since 2009 and a 65 million dollar round in 2024, against a vendor founded in 2022 with no longitudinal record.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. RAAPID and Reveleer are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | RAAPID | Reveleer |
|---|---|---|
| Primary category | Value Based Care Intelligence | Value Based Care Intelligence |
| Founded | 2022 | 2009 |
| Headquarters | Louisville, Kentucky, United States | Glendale, California, United States |
| Website | raapidinc.com | reveleer.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards RAAPID its top capability grade on AI Centrality and Deployment Model and Data Residency. Set against Reveleer, RAAPID grades higher on several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index records no top capability grade for Reveleer on any axis it scores. Set against RAAPID, Reveleer does not grade higher on any scored axis, though the two are level on several axes, including Autonomy and Oversight Model, Clinical and Operational Evidence and AI Safety and PHI Stewardship. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose RAAPID or Reveleer?
The AI Health Index grades RAAPID higher than Reveleer on every axis that separates them, several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure. Reveleer does not grade higher on any scored axis.
Where do RAAPID and Reveleer differ most?
The widest separation the AI Health Index records between RAAPID and Reveleer is on Deployment Model and Data Residency, where RAAPID grades A and Reveleer grades C. That axis sits in the Integration and Deployment group, so it should carry the most weight for a buyer whose binding constraint is how the product lands in the stack already in place.
Where do RAAPID and Reveleer grade the same?
The AI Health Index grades RAAPID and Reveleer the same on several axes, including Autonomy and Oversight Model, Clinical and Operational Evidence and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have RAAPID and Reveleer not disclosed?
At the last review, at least one of RAAPID and Reveleer published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Autonomous Medical Coding page.
Both are graded on vendor reported evidence with no independent validation located, and neither publishes SOC 2, HIPAA, a PHI framework, or pricing, which for vendors processing complete medical records across health plan populations is a real diligence gap.
RAAPID's accuracy figures are vendor stated, and its asserted industry baseline of 20 to 30 percent accuracy is a striking claim about competitors that no cited source supports; whether neuro symbolic is technically distinctive or a naming choice cannot be verified from public materials. Reveleer's retrieval first orientation is retrospective look back rather than point of care, and its AI sits over a business whose core value predates it. Both offer managed services alongside software, which carry different economics a buyer should separate.